Proactive Investors - Run By Investors For Investors
Why invest in OPTI?
OptiBiotix Health plc: DEEP DIVE
OVERVIEW

OptiBiotix’s SlimBiome gathers steam with slew of deals as subsidiary eyes potential IPO

A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
Weight loss
OVERVIEW: OPTI The Big Picture
SlimBiome aims to help reduce weight by replacing self-denial with shrinkflation - feeling fuller for longer to decrease food intake

Life sciences firm OptiBiotix Health plc (LON:OPTI) has clinched a number of deals for its SlimBiome weight loss product as the company eyes up a potential initial public offering (IPO).

In January, the group inked an agreement with Indian firm Zeon Lifesciences Ltd, granting it an exclusive licence to manufacture and supply SlimBiome in the return in return for a 50% share of the profits.

WATCH: OptiBiotix’s SlimBiome gathers steam as subsidiary eyes potential IPO

Zeon is India’s leading manufacturer of nutraceutical and herbal products with expertise in developing custom formulations for the food, herbal, and pharmaceutical industries. The company's customers have included French food giant Danone as well as multinational Indian pharma firm Sun Pharmaceutical.

Aside from manufacturing the product, Zeon will also cover the registration costs of SlimBiome and any products containing it with the Food Safety and Standard Authority of India.

Stephen O'Hara, chief executive of OptiBiotix, said that the deal with Zeon was “an important step in optimising the supply chain to facilitate the needs of existing and new corporate partners in India and Southern Asia”.

READ: OptiBiotix jumps as it inks supply and profit sharing agreement for SlimBiome in India

The agreement with Zeon is the ninth deal for SlimBiome that the company has secured, and also the fifth manufacturing agreement.

In a note to clients, analysts at City broker finnCap said the deal was “another example of the building blocks OptiBiotix continues to put in place to commercialise its technology platforms”, adding that while it was “still too early to make meaningful forecasts”, the group’s commercial footprint “continues to expand with highly relevant and experienced partners”.

EEA traction

The deal in India follows on from a production, packaging and supply agreement for SlimBiome signed in November with Italian firm Nutrilinea, who will formulate and distribute SlimBiome Medical in boxes of 30 single sachet doses for sale across its network as well as to Opti’s growing list of partners.

READ: OptiBiotix Health signs production and supply agreement for weight loss product

The action in Europe didn’t stop there, as in December the firm secured a distributor for SlimBiome in Greece and the island nation of Cyprus.

The agreement grants the distributor exclusive distribution rights in Greece and Cyprus and first right of refusal for the Gulf States in return for meeting annual sales targets to retain exclusivity.

READ: OptiBiotix Health signs distribution deal covering Greece and Cyprus for SlimBiome Medical

It isn’t the first time Opti has received good news from Greece and Cyprus, having also secured a three-year distribution contract for its LPLDL cholesterol and blood pressure product which covers the two countries.

CE Marked

The company received a boost at the end of November when SlimBiome was granted a CE mark, allowing it to be marketed within the European Economic Area (EEA) as well as providing eligibility for shortened medical product registration procedures in other markets such as China and the United Arab Emirates.

READ: OptiBiotix surges as SlimBiome granted CE mark and medical device status

CE-marked products may also make medicinal or medical claims supported by clinical studies, a factor that would extend the application of SlimBiome from food products to medical products.

Subsidiary raises funds with eyes on IPO

Not wanting to be left out of the news cycle, Opti’s subsidiary, ProBiotix Health Limited, raised £1mln in mid-December to fund a potential IPO.

The spin-out forms a key part of Opti’s strategy of forming separate divisions that can eventually be spun out to form separate legal entities.

READ: OptiBiotix subsidiary raises £1mln to fund potential IPO

The money was raised through the issue of convertible loan notes, of which Opti has subscribed for around £250,000-worth. O'Hara has subscribed for £25,000 while certain close family members had subscribed for £265,000. In addition, Per Rehné, the company’s commercial director, subscribed for £25,000. The remaining subscribers include two institutional investors and two industry partners.

The CLNs can be converted at a 50% discount to the issue price of ProBiotix shares in the event of an IPO.

Strong share performance

The slew of deals hasn’t been lost on the market either, with the share price having risen around 40% over the last 12 months.

As of 7 January 2019, OptiBiotix shares are trading at around 94p, giving it a market cap of £77.1mln.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use